Inversago Pharma is a clinical stage biopharmaceutical company dedicated to developing therapies for patients suffering from metabolic and fibrotic diseases. The company is the leader in the development of peripherally acting CB1 receptor (CB1r) blocker therapies designed to help patients with complications associated with metabolic and fibrotic diseases.

Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy, Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).

JDRF T1D Fund

AQC Capital

Anges Quebec

Genesys Capital

adMare Bio Innovations

Amorchem

Fonds de solidarité FTQ

Forbion Capital Partners

New Enterprise Associates

Amgen Ventures

Inversago Pharma

This #WorldDiabetesDay, know your risk, know your response.
Today and all of November, learn more about diabetes prevention, management and self-care on diabetes.ca

I just heard that the acquisition of Inversago by Novo Nordisk has made the 2023 official finalist roster of the European Lifestars Awards! This is true testament to the strategic fit and the value potential of the deal. Great news I wanted to share this morning:

https://lnkd.in/eFkfbGeT


We have now officially closed the acquisition of Inversago Pharma. With this acquisition, we aim to build on our ability to offer innovative medicines to people living with serious chronic diseases. 
 
A warm welcome to our new colleagues - your expertise and talents are a valuable addition to our team!
 
Learn more about this from our Executive Vice President, Martin Holst Lange here 👇

Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases

This Canada day, we're highlighting a great Canadian biotech company from the Genesys portfoliol! 🇨🇦 🍁 

Key data captured by Stifel group at the #ada2023 conference, highlighting Inversago Pharma     

- Inversago showed impressive CB1 inverse agonist Ph1 obesity data, fixing historical safety issues associated with the target.

- Inversago showed weight reduction data similar in magnitude to what has been accomplished with GLP-1s. More importantly, CB1R MoA is orthogonal to what others are doing and could be used as an ideal candidate for combination approaches.

- Inversago’s INV-202 4 week weight loss data is impressive in when comparing to other drugs (including GLP-1s).

Just finishing up an exciting #ada2023 where I had the amazing opportunity to present #InversagoPharma’s phase 1B data. It is so exciting to see scientific research lead to potential new treatments, truly from the bench to the bedside! Looking forward to bringing this potential treatment to patients suffering from complications of obesity and diabetes.

COM:INVERSAGO

Inversago Pharma

Analysis Not Available